Effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ based on propensity score matching

WU Yang; YUAN Chengjia; YANG Die; ZHANG Xiaochun

doi:10.7619/jcmp.20231064

Journal of Clinical Medicine in Practice > 2023 > 27(14): 46-50, 57. > DOI: 10.7619/jcmp.20231064

WU Yang, YUAN Chengjia, YANG Die, ZHANG Xiaochun. Effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ based on propensity score matching[J]. Journal of Clinical Medicine in Practice, 2023, 27(14): 46-50, 57. DOI: 10.7619/jcmp.20231064

Citation:

PDF (1323 KB)

Effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ based on propensity score matching

1.
Medical College of Yangzhou University, Yangzhou, Jiangsu, 225003
2.
Department of Oncology, Yangzhou City Hospital of Traditional Chinese Medicine of Jiangsu Province, Yangzhou, Jiangsu, 225127

More Information

Received Date: April 03, 2023
Revised Date: May 29, 2023
Available Online: July 30, 2023

Graphical Abstract

Abstract

Abstract

Objective
To explore the effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ in a real-world environment.
Methods
From January 1, 2012 to December 1, 2022, 433 patients with gastric cancer who met the inclusion criteria were collected as research objects and divided into the Shenmai group (treated with traditional Chinese and western medicine) and the control group (treated with western medicine). Propensity score matching (PSM) was used to balance the confounding factors between groups; the Cox regression model was used to evaluate the risk factors for prognosis of gastric cancer; the Kaplan-Meier method and Log-rank test were used to compare the overall survival (OS) and progression free survival (PFS) of patients in both groups.
Results
A total of 433 patients met the inclusion criteria were enrolled in this study, and were assigned into two groups after PSM, with 65 cases in each group. After PSM, the median OS and PFS in the Shenmai group were 35.27 and 22.63 months respectively, which were significantly longer than 17.83 and 14.97 months in the control group (P < 0.001, P=0.003). After PSM, the 1-, 3- and 5-year survival rates in the Shenmai group were 90.7%, 49.3% and 34.8% respectively, which were significantly higher than 67.7%, 19.8% and 4.9% in the control group (χ²=21.983, P < 0.001). Multivariable analysis of survival prognosis showed that the independent risk factors influencing gastric cancer were vascular invasion (P=0.046), adenocarcinoma with signet-ring cell carcinoma (P=0.001), phase Ⅲa (P=0.012), phase Ⅲb (P=0.035) and phase Ⅲc (P=0.046) of TNM staging. Shenmai Injection combined with Aidi injection (P < 0.001), Yadanzi Injection (P=0.001), radical surgery (P=0.004) and chemotherapy (P=0.005) were able to benefit the survival of gastric cancer patients.
Conclusion
The combination of Shenmai Injection and western medicine has more advantages than simple western medicine treatment in treating patients with gastric cancer in phase Ⅱ to Ⅲ.
- real-world researches,
- propensity score matching,
- gastric cancer,
- Shenmai Injection,
- survival

FullText(HTML)

References (10)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648. doi: 10.1016/S0140-6736(20)31288-5
[3]	张国平, 李攀, 费浙钧, 等. 参麦注射液联合FOLFOX方案化疗治疗进展期胃癌近期疗效及对患者免疫功能和肿瘤标志物的影响[J]. 中国基层医药, 2021, 28(12): 1839-1843.
[4]	孙慧. 参麦注射液治疗消化系统恶性肿瘤的临床疗效分析[J]. 黑龙江医药, 2012, 25(4): 595-597. https://www.cnki.com.cn/Article/CJFDTOTAL-HJYY201204047.htm
[5]	刘包欣子, 邵杰, 舒鹏, 等. FOLFOX4方案联合参麦注射液对胃癌患者骨髓功能和免疫功能的影响[J]. 西部中医药, 2020, 33(9): 8-11. https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY202009003.htm
[6]	杨蝶, 张禹森, 张晓春. 复方苦参注射液对胃癌患者生存期的影响: 一项真实世界回顾性、多中心队列研究[J]. 中医杂志, 2022, 63(23): 2259-2265. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202223011.htm
[7]	刘学梅, 段世玲, 刘勇峰. 参麦注射液联合化疗治疗进展期胃癌29例[J]. 河南中医, 2015, 35(9): 2285-2287. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201509124.htm
[8]	张艳, 周淑如, 韩仕阳, 等. 人参皂苷对免疫功能的调节作用及机制[J/OL]. 江苏大学学报(医学版): 1-9[2022-12-16].
[9]	王冬雪, 吴新民, 蔺冬梅, 等. 人参皂苷抗胃癌作用研究进展[J]. 特产研究, 2022, 44(3): 118-123, 128. https://www.cnki.com.cn/Article/CJFDTOTAL-TCYA202203019.htm
[10]	杨婧, 孙超, 姜泽群, 等. 麦冬皂苷B对人胃癌MGC-803细胞侵袭和迁移能力的影响[J]. 中华中医药杂志, 2019, 34(6): 2742-2745. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906110.htm

[1]	SHEN Yi, JING Ying. Efficacy of Aiyu Capsule combined with FOLFOX4 chemotherapy in treatment of median or advanced rectum cancer and its impacts on cellular immunity and survival[J]. Journal of Clinical Medicine in Practice, 2024, 28(23): 58-64. DOI: 10.7619/jcmp.20242114
[2]	GAO Qingling, CHANG Yan, WANG Jingni, ZHANG Jing, SUN Qingke. Effects of individual or combination medication of epidermal growth factor receptor tyrosine kinase inhibitor combined with chemotherapy on progression-free survival in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation[J]. Journal of Clinical Medicine in Practice, 2023, 27(24): 1-6. DOI: 10.7619/jcmp.20233042
[3]	WU Xin, LIANG Bo. Construction of a postoperative survival nomogram for breast cancer based on ultrasound and cancer indicators[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 62-68. DOI: 10.7619/jcmp.20213928
[4]	XING Haiyang, ZHANG Yandi, WANG Kexin. Analysis on effect of radiotherapy on the survival of cervical cancer based on SEER database[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 15-19. DOI: 10.7619/jcmp.202006005
[5]	ZHU Yaodong, ZHANG Mei, LI Ping. Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis[J]. Journal of Clinical Medicine in Practice, 2019, 23(9): 20-23. DOI: 10.7619/jcmp.201909006
[6]	YUAN Yuan, YUAN Huaihong, ZHOU Li. Survival situation analysis of elderly patients with hemodialysis[J]. Journal of Clinical Medicine in Practice, 2017, (17): 89-91,95. DOI: 10.7619/jcmp.201717026
[7]	XING Ze, WANG Hua, HU Qun, ZHAO Haiyan, SU Wuyun. Risk factors and survival analysis of locally advanced non-small cell lung cancer with brain metastasis[J]. Journal of Clinical Medicine in Practice, 2015, (23): 24-27. DOI: 10.7619/jcmp.201523008
[8]	XU Zhijuan. Influence of self-nursing on survival quality of esophageal carcinoma patients treated by radiotherapy[J]. Journal of Clinical Medicine in Practice, 2013, (22): 32-34. DOI: 10.7619/jcmp.201322012
[9]	ZHOU Yunxia, ZHOU Yuefeng, HUANG Chengmei. Comparison of influence of different nursing models on comprehensive survive conditions in burn paitents[J]. Journal of Clinical Medicine in Practice, 2013, (12): 102-104. DOI: 10.7619/jcmp.201312038

Cited By

Cited by

Periodical cited type(1)

郭秀兰，杨燕琼，侯雅真，石洁，陈琛. NRS2002与MUST结合评估辅助个体化营养支持对淋巴瘤化疗患者营养状态与并发症的影响. 中外医学研究. 2024(24): 91-94 .

Other cited types(0)

Get Citation

PDF

XML

Article views (148) PDF downloads (12) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ based on propensity score matching